After strong Q2 results and positive legal news, is GSK’s share
GSK saw core operating profit jump in Q2 and won the latest round in its ongoing legal case, making the share price look even more undervalued to me. The post After strong Q2 results …
OFF
GSK Shares Jump After Drugmaker Boosts Outlook, Positive …
2 weeks from now
4 days ago · American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales …
wsj.com
OFF
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
2 weeks from now
GSK plc GSK reported core earnings of $1.09 per American depositary share (ADS) in second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.Core earnings rose 12% year …
yahoo.com
OFF
GSK Delivers Strong 2024 Performance With Further Improvement …
2 weeks from now
4 days ago · £2 billion share buyback programme to be implemented over the next 18 months; 2025 guidance and further improvement to long-term outlooks. Expect 2025 turnover growth of …
gsk.com
OFF
GSK's Share Price Increases 6% After Positive Results For FY 2024. It ...
2 weeks from now
The Motley Fool GSK’s share price rose 6% in the morning, after it published its surprisingly positive full-year 2024 results. Sales and revenue were among the metrics that exceeded …
finvestly.com
OFF
GSK Pharma Stock Gains Over 3% After Profit, Revenue Boost In Q2 ...
2 weeks from now
Oct 29, 2024 · Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s intraday trade. The stock rose after the …
business-standard.com
OFF
GSK Delivers Strong Q2 Sales Of £8.1 Billion, +6% AER, +15% CER …
2 weeks from now
Jul 28, 2021 · Continue to expect strong growth from Shingrix in H2; Consumer Healthcare £2.3 billion -4% AER, +3% CER (+7% CER excluding divestments/brands under review) Effective …
gsk.com
OFF
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces
2 weeks from now
Jul 26, 2023 · Biogen’s Q2 Earnings: Biogen reported better-than-expected second-quarter 2023 results as earnings and sales both beat estimates. Adjusted earnings per share of $4.02 easily …
nasdaq.com
OFF
GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...
2 weeks from now
3 days ago · GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and …
reuters.com
OFF
GSK Launches £2bn Share Buyback And Upgrades Sales Forecast
2 weeks from now
3 days ago · Strong growth in HIV, oncology and specialty medicines have offset a 4 per cent decline in vaccine sales
thetimes.com
OFF
GSK (GSK) Expected To Beat Earnings Estimates: What To Know …
2 weeks from now
Jul 19, 2023 · This drug developer is expected to post quarterly earnings of $0.85 per share in its upcoming report, which represents a year-over-year change of -2.3%. Revenues are expected …
yahoo.com
OFF
GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback …
2 weeks from now
3 days ago · The results reflected accelerating momentum in Specialty Medicines offsetting lower Vaccine sales. In pre-market activity on the NYSE, GSK shares were trading at $37.09, up …
businessinsider.com
OFF
GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …
2 weeks from now
3 days ago · Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted due to favorable price impacts in the year-ago period, continued growth in ex-U.S. …
nasdaq.com
FAQs about After strong Q2 results and positive legal news, is GSK’s share Coupon?
Why did GSK Pharma stock rise in q2fy25?
Is GSK transforming top-line growth into shareholder value?
Will GSK raise its guidance to £40 billion by 2031?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
